ADRB2 CANCER MARKERS

• US 20090075833A1
• Filed: 01/18/2008
• Published: 03/19/2009
• Est. Priority Date: 01/19/2007
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Original Assignee: Board of Regents of the University of Michigan (University of Michigan)
• Inventors: Chinnaiyan, Arul M., Mehra, Rohit, Yu, Jindan
• Granted Patent: US 8,058,003 B2
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ADRB2 markers for cancer.

Claims

1. A method for identifying cancer in a patient, comprising detecting underexpression of Adrenergic Receptor, Beta 2 (ADRB2) compared to normal expression of ADRB2 in a sample from a patient, wherein detecting in the sample underexpression of ADRB2 compared to normal expression of ADRB2 identifies cancer in said patient.

2. The method of claim 1, wherein said cancer is prostate cancer.

3. The method of claim 1, wherein underexpression of ADRB2 in said sample compared to normal expression of ADRB2 is indicative of metastatic prostate cancer in said patient.

4. The method of claim 1, wherein said sample is a biopsy sample.

5. The method of claim 1, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 nucleic acid in said sample.

6. The method of claim 5, wherein said detecting the level of ADRB2 nucleic acid in said sample comprises detecting the level of ADRB2 mRNA in said sample.

7. The method of claim 6, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises a detection technique selected from the group consisting of microarray analysis, reverse transcriptase PCR, quantitative reverse transcriptase PCR, and hybridization analysis.

8. The method of claim 1, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 polypeptide in said sample.

9. A method for identifying risk of clinical failure in a patient, comprising detecting underexpression of Adrenergic Receptor, Beta 2 (ADRB2) compared to normal expression of ADRB2 in a sample from a patient, wherein detecting in the sample underexpression of ADRB2 compared to normal expression of ADRB2 identifies said patient as being at risk of clinical failure.

10. The method of claim 9, wherein said clinical failure comprises an outcome selected from the group consisting of an increase of 0.2 ng ml⁻

1 PSA and recurrence of disease after prostatectomy.

11. The method of claim 10, wherein said recurrence of disease after prostatectomy comprises development of metastatic cancer.

12. The method of claim 9, wherein said sample is a biopsy sample.

13. The method of claim 9, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 nucleic acid in said sample.

14. The method of claim 13, wherein said detecting the level of ADRB2 nucleic acid in said sample comprises detecting the level of ADRB2 mRNA in said sample.

15. The method of claim 14, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises a detection technique selected from the group consisting of microarray analysis, reverse transcriptase PCR, quantitative reverse transcriptase PCR, and hybridization analysis.

16. The method of claim 9, wherein said detecting underexpression of ADRB2 compared to normal expression of ADRB2 in said sample comprises detecting the level of ADRB2 polypeptide in said sample.